Our collaborations

Illumina are a world-leading sequencing and technology provider, dominating the NGS space for over a decade. Origin Sciences and Illumina have embarked on various collaborations from process refinement, technology optimisation and supporting ongoing Illumina technology development. Custom development and Illumina expertise have enabled these technologies to deliver the depth and precision needed to interrogate human mutation and methylation states, in conjunction with microbial meta-analysis, powering the creation our hologenomic assays.

Azenta are a global enterprise with capabilities to deliver Next Generation Sequencing (NGS) globally. In collaboration with Azenta and illumina, tailored facilities have been implemented to rapidly deliver high-quality cost-effective data in their new Genomics Laboratory (Oxford). This collaboration has enabled dedicated processes, practices and instrumentation to enable high-throughput sequencing, supporting the final test development, but also providing an established framework for test delivery.

Theiagen’s analytical expertise, infrastructure and pipelines support rapid analysis, reporting and deployment of data. These computational biology expertise have supported the integration of multi-layered genomic data, from host mutations and methylation profiles to biome signatures, allowing rapid reporting of actionable hologenomic insights.

The NovaCyt group have a strong footprint in molecular biology and developing commercial diagnostic testing platforms. In collaboration, Origin Sciences and NovaCyt have developed a scalable and automatable, bespoke nucleic acid extraction system, that outperforms all commercially available alternatives assessed. This assay is automation platform agnostic and is tailored to optimise the recovery of DNA from mucus specimens, enhancing the utility of our biospecimen and diagnostic performance. A novel extraction platform for a novel biospecimen.

The Quadram Institute brings together researchers, academics and NHS clinicians to address global challenges in human health and disease. Providing world-leading expertise in microbiology and gastrointestinal health, collaborative projects with Quadram have accelerated our understanding of the microbiome. This combined research has been fundamental in developing our hologenomic approach, combining the utility of the biome with in-depth mutation and methylation signatures to understand the host-microbiome landscape and interactions.

It is well known that many identified biomarkers never make it to the clinic, through a combination of poor analytical methods and ineffective demonstration of clinical utility. Our collaboration with Imperial focuses on biomarker discovery methodologies, validation of findings and diagnostic utility, ensuring pathways to adoption, taking research from ‘bench to bedside’.